Contact

All Stories

  1. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth

    Article • The Lancet, March 2024, Elsevier

    Shumaila Nargus, Gerald Chi, Dr Edmond Sanganyado, ED Doris V. Ortega-Altamirano, Dr Manpreet Singh Bhatti, Dr Mohammed Kuddus, Mr Ferry Efendi, Dr Senbagam Duraisamy, Sumaira Mubarik, Dr arnaud Iradukunda, Prof Tommi Vasankari, Dr Yuan-Pang Wang, Prof. Muayyad M Ahmad, Prof. Atanu Biswas, Javier Abednego Magaña Gomez, Dr Sonu Bhaskar, Ts. Dr Adel Al-Gheethi, Assistant Professor Ashok Pandey, Dr. Tungki Pratama Umar, Dr Amr Hassan, Dr Javad Sharifi Rad, Dr Ali Fatehizadeh, Mr. Ahmednur Adem Aliyi

  2. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

    Article • The Lancet Neurology, March 2024, Elsevier

    Shumaila Nargus, Gerald Chi, ED Doris V. Ortega-Altamirano, Dr Senbagam Duraisamy, Sumaira Mubarik, Professor Yousef Khader, Prof Tommi Vasankari, Dr Yuan-Pang Wang, Prof. Atanu Biswas, Dr Sonu Bhaskar, Ts. Dr Adel Al-Gheethi, Assistant Professor Ashok Pandey, Dr Amr Hassan, Dr Ali Fatehizadeh, Mr. Ahmednur Adem Aliyi, Professor Erkin Mirrakhimov

  3. Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

    Article • Frontiers in Cardiovascular Medicine, January 2024, Frontiers

    Gerald Chi

  4. Global Burden of Cardiovascular Diseases and Risks, 1990-2022

    Article • Journal of the American College of Cardiology, December 2023, Elsevier

    Gerald Chi, Shumaila Nargus, Professor Erkin Mirrakhimov, Laszlo Lorenzovici, Dr. Saurab Sharma, Ph.D., Dr. Tungki Pratama Umar, ED Doris V. Ortega-Altamirano, Dr Mohammed Kuddus, Prof Tommi Vasankari, Dr Yuan-Pang Wang, Prof. Muayyad M Ahmad, Javier Abednego Magaña Gomez, Dr Amr Hassan, Dr Ali Fatehizadeh

  5. Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping Review

    Article • Clinical Therapeutics, November 2023, Elsevier

    Gerald Chi

  6. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

    Article • The Lancet Global Health, October 2023, Elsevier

    Dr. Ahmed I. Hasaballah, Gerald Chi, Professor Erkin Mirrakhimov, Dr Sonu Bhaskar, Professor Stefan Lorkowski

  7. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, February 2023, Oxford University Press (OUP)

    Gerald Chi

  8. The Relationship Between the Age of First Acute Coronary Syndrome Episode and Internal Migration

    Article • Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, January 2023, Turkish Society of Cardiology

    Gerald Chi

  9. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial

    Article • Journal of Thrombosis and Thrombolysis, December 2022, Springer Science + Business Media

    Gerald Chi

  10. Association of D-dimer with short-term risk of venous thromboembolism in acutely ill medical patients: A systematic review and meta-analysis

    Article • Vascular Medicine, August 2022, SAGE Publications

    Gerald Chi

  11. Factors associated with recurrent spontaneous coronary artery dissection: a systematic review and meta-analysis

    Article • Coronary Artery Disease, July 2022, Wolters Kluwer Health

    Gerald Chi

  12. Systematic Review and Meta-Analysis of Thromboprophylaxis with Heparins Following Intracerebral Hemorrhage

    Article • Thrombosis and Haemostasis, June 2022, Thieme Publishing Group

    Gerald Chi

  13. Intracranial Pressure Monitoring in Moderate Traumatic Brain Injury: A Systematic Review and Meta-Analysis

    Article • Neurocritical Care, May 2022, Springer Science + Business Media

    Gerald Chi

  14. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

    Article • Current Atherosclerosis Reports, May 2022, Springer Science + Business Media

    Gerald Chi

  15. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis

    Article • Biomarkers in Medicine, April 2022, Future Medicine

    Gerald Chi

  16. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial

    Article • Thrombosis Research, March 2022, Elsevier

    Gerald Chi

  17. Abstract P199: Association Of High Left Ventricular Ejection Fraction With Incident Heart Failure, And Impact Of Adiposity On Ejection Fraction

    Article • Circulation, March 2022, Wolters Kluwer Health

    Gerald Chi

  18. MIGRAINE HEADACHE IN PATIENTS WITH SPONTANEOUS CORONARY ARTERY DISSECTION: A REPORT OF THE ISCAD REGISTRY

    Article • Journal of the American College of Cardiology, March 2022, Elsevier

    Gerald Chi

  19. Early and late recurrent cardiovascular events among high‐risk patients with an acute coronary syndrome: Meta‐analysis of phase III studies and implications on trial design

    Article • Clinical Cardiology, January 2022, Wiley

    Gerald Chi

  20. Clinical outcomes of pharmacological thromboprophylaxis among patients with intracerebral hemorrhage: Systematic review and meta-analysis

    Article • Clinical Neurology and Neurosurgery, January 2022, Elsevier

    Gerald Chi

  21. Association of Cholesterol Efflux Capacity with Adverse Cardiovascular Outcomes: A Meta-Analysis†

    Article • Journal of Clinical Lipidology, January 2022, Elsevier

    Gerald Chi

  22. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, January 2022, SAGE Publications

    Gerald Chi

  23. Early and Late Recurrent Cardiovascular Risk in Patients With Recent Acute Coronary Syndrome: Meta-Analysis and Implications in Trial Design†

    Article • Journal of Clinical Lipidology, January 2022, Elsevier

    Gerald Chi

  24. Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis

    Article • Frontiers in Cardiovascular Medicine, December 2021, Frontiers

    Gerald Chi

  25. Association between obesity grade and the age of the first acute coronary syndrome: A cross-sectional observational study

    Article • International Journal of Cardiology, December 2021, Elsevier

    Gerald Chi

  26. Cholesterol Efflux Capacity and Measurement Assays: A Novel Biomarker of High-Density Lipoprotein (HDL) Function

    Article • American Heart Journal, December 2021, Elsevier

    Gerald Chi

  27. Biological Basis and Proposed Mechanism of Action of CSL112 (Apolipoprotein A-I [Human]) for Prevention of Major Adverse Cardiovascular Events in Patients post Myocardial Infarction

    Article • American Heart Journal, December 2021, Elsevier

    Gerald Chi

  28. Evaluation of Cardiac Troponin and Adverse Outcomes After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

    Article • Neurocritical Care, October 2021, Springer Science + Business Media

    Gerald Chi

  29. Effect of Azithromycin and Hydroxychloroquine in Patients Hospitalized with COVID‐19: Network Meta‐Analysis of Randomized Controlled Trials

    Article • Journal of Medical Virology, August 2021, Wiley

    Gerald Chi

  30. Independent and incremental prognostic value of D-dimer in hospitalized COVID-19 patients

    Article • Future Virology, July 2021, Future Medicine

    Gerald Chi

  31. Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients

    Article • Therapeutics and Clinical Risk Management, May 2021, Taylor & Francis

    Gerald Chi

  32. ASSOCIATION OF CHOLESTEROL EFFLUX CAPACITY WITH ADVERSE CARDIOVASCULAR OUTCOMES - A META-ANALYSIS

    Article • Journal of the American College of Cardiology, May 2021, Elsevier

    Gerald Chi

  33. EARLY AND LATE RECURRENT CARDIOVASCULAR RISK IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME - META-ANALYSIS AND IMPLICATIONS IN TRIAL DESIGN

    Article • Journal of the American College of Cardiology, May 2021, Elsevier

    Gerald Chi

  34. Association between red blood cell distribution width and mortality and severity among patients with COVID‐19: A systematic review and meta‐analysis

    Article • Journal of Medical Virology, January 2021, Wiley

    Gerald Chi

  35. The Role of Interleukin-27 in Atherosclerosis: A Contemporary Review

    Article • Cardiology, January 2021, Karger Publishers

    Gerald Chi

  36. COVID-19: A double threat to takotsubo cardiomyopathy and spontaneous coronary artery dissection?

    Article • Medical Hypotheses, January 2021, Elsevier

    Gerald Chi

  37. Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

    Article • Journal of Clinical Medicine, August 2020, MDPI AG

    Gerald Chi

  38. Extended Thromboprophylaxis with Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients

    Article • Critical Pathways in Cardiology A Journal of Evidence-Based Medicine, July 2020, Wolters Kluwer Health

    Gerald Chi

  39. Differential effect of ticagrelor on irreversible harms in diabetes

    Article • The Lancet, July 2020, Elsevier

    Gerald Chi

  40. Attention and citation: Common interests of researchers and journals

    Article • Research and Practice in Thrombosis and Haemostasis, March 2020, Wiley

    Gerald Chi

  41. Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)

    Article • The American Journal of Cardiology, March 2020, Elsevier

    Gerald Chi

  42. Coronary artery tortuosity

    Article • Coronary Artery Disease, March 2020, Wolters Kluwer Health

    Gerald Chi

  43. Effect of Vitamins and Dietary Supplements on Cardiovascular Health

    Article • Critical Pathways in Cardiology A Journal of Evidence-Based Medicine, February 2020, Wolters Kluwer Health

    Gerald Chi

  44. Machine learning to predict venous thrombosis in acutely ill medical patients

    Article • Research and Practice in Thrombosis and Haemostasis, January 2020, Wiley

    Gerald Chi

  45. The AngelMed Guardian® System in the Detection of Coronary Artery Occlusion: Current Perspectives

    Article • Medical Devices Evidence and Research, January 2020, Taylor & Francis

    Gerald Chi

  46. Spontaneous coronary artery dissection managed with a conservative or revascularization approach

    Article • Journal of Cardiovascular Medicine, January 2020, Wolters Kluwer Health

    Gerald Chi

  47. Prognostic Value of Biomarkers in Cardiac Allograft Vasculopathy following Heart Transplantation: A Literature Review

    Article • Cardiology, January 2020, Karger Publishers

    Gerald Chi

  48. Smartwatch for the Detection of Atrial Fibrillation

    Article • Critical Pathways in Cardiology A Journal of Evidence-Based Medicine, December 2019, Wolters Kluwer Health

    Gerald Chi

  49. Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study

    Article • Catheterization and Cardiovascular Interventions, September 2019, Wiley

    Gerald Chi

  50. Spontaneous coronary artery dissection and associated myocardial bridging: Current evidence from cohort study and case reports

    Article • Medical Hypotheses, July 2019, Elsevier

    Gerald Chi

  51. Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection

    Article • The American Journal of Cardiology, June 2019, Elsevier

    Gerald Chi

  52. Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry

    Article • Catheterization and Cardiovascular Interventions, April 2019, Wiley

    Gerald Chi

  53. Social media optimization in medicine: A journal's perspective

    Article • Research and Practice in Thrombosis and Haemostasis, April 2019, Wiley

    Gerald Chi

  54. Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial

    Article • TH Open, April 2019, Thieme Publishing Group

    Gerald Chi

  55. PARADOXICAL PROTECTIVE EFFECT OF OBESITY ON THE RISK OF VENOUS THROMBOEMBOLISM: OBSERVATIONS FROM APEX TRIAL

    Article • Journal of the American College of Cardiology, March 2019, Elsevier

    Gerald Chi

  56. Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients

    Article • Circulation, February 2019, Wolters Kluwer Health

    Gerald Chi

  57. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy

    Article • Intensive Care Medicine, February 2019, Springer Science + Business Media

    Gerald Chi

  58. Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: Updated meta-analysis of randomized trials

    Article • Vascular Medicine, February 2019, SAGE Publications

    Gerald Chi

  59. Chikungunya Virus Infection-related Rhabdomyolysis: A Case Report

    Article • Cureus, February 2019, Cureus, Inc.

    Gerald Chi

  60. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

    Article • American Heart Journal, February 2019, Elsevier

    Gerald Chi

  61. Eosinophilic Inflammation In Spontaneous Coronary Artery Dissection: Agent Provocateur Or Innocent Bystander?

    Article • December 2018, Science Trends

    Gerald Chi

  62. Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target?

    Article • Medical Hypotheses, December 2018, Elsevier

    Gerald Chi

  63. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial

    Article • Thrombosis and Haemostasis, November 2018, Thieme Publishing Group

    Gerald Chi

  64. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial

    Article • American Journal of Hematology, October 2018, Wiley

    Gerald Chi

  65. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism

    Article • Expert Review of Cardiovascular Therapy, October 2018, Taylor & Francis

    Gerald Chi, Sadaf Sharfaei, M.D. Farima Kahe

  66. Continuous Thoracic Paravertebral Block as Perioperative Analgesia for Off-Pump Coronary Artery Bypass Grafting

    Article • Journal of Cardiovascular Disease Research, August 2018, EManuscript Services

    Gerald Chi

  67. D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)

    Article • The American Journal of Cardiology, August 2018, Elsevier

    Gerald Chi

  68. P1623Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  69. P251Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  70. 4321Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  71. 1460Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  72. P6072Characterization of major and clinically relevant non-major bleeding in the APEX trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  73. 2160Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  74. 109Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Gerald Chi

  75. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the Apex Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended...

    Article • Journal of Vascular Surgery Venous and Lymphatic Disorders, July 2018, Elsevier

    Gerald Chi

  76. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention

    Article • Journal of Thrombosis and Thrombolysis, June 2018, Springer Science + Business Media

    Gerald Chi

  77. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis

    Article • Journal of Thrombosis and Thrombolysis, June 2018, Springer Science + Business Media

    Gerald Chi

  78. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients following percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial

    Article • American Heart Journal, June 2018, Elsevier

    Gerald Chi

  79. Scleral exposure alterations following Le Fort I osteotomy (with and without maxillary impaction) in skeletal class III patients: A before-and-after clinical trial

    Article • Journal of Cranio-Maxillofacial Surgery, June 2018, Elsevier

    Gerald Chi

  80. Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy

    Article • Medical Hypotheses, May 2018, Elsevier

    Gerald Chi

  81. Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials

    Article • Clinical and Experimental Hypertension, April 2018, Taylor & Francis

    Gerald Chi, M.D. Farima Kahe

  82. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

    Article • JACC Cardiovascular Interventions, April 2018, Elsevier

    Gerald Chi

  83. Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: an APEX Trial Substudy

    Article • The American Journal of Medicine, April 2018, Elsevier

    Gerald Chi

  84. COMPARATIVE EFFICACY AND SAFETY OF RIVAROXABAN-BASED DUAL-PATHWAY ANTITHROMBOTIC THERAPY VERSUS DUAL ANTIPLATELET THERAPY: A POOLED ANALYSIS OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS

    Article • Journal of the American College of Cardiology, March 2018, Elsevier

    Gerald Chi

  85. High-Density Lipoprotein-Targeted Therapy for Coronary Heart Disease: is the HDL Hypothesis Operational or Defunct?

    Article • Current Trends in Biomedical Engineering & Biosciences, February 2018, Juniper Publishers

    Gerald Chi

  86. Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial

    Article • TH Open, January 2018, Thieme Publishing Group

    Gerald Chi

  87. Characterisation of Access Site Versus Non-Access Site Bleeding After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation

    Article • January 2018, Elsevier

    Gerald Chi

  88. Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

    Article • British Journal of Cardiology, January 2018, Medinews (Cardiology), Ltd.

    Gerald Chi

  89. Surface Microbiology of Smartphone Screen Protectors Among Healthcare Professionals

    Article • Cureus, December 2017, Cureus, Inc.

    Gerald Chi

  90. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients

    Article • Circulation, December 2017, Wolters Kluwer Health

    Gerald Chi

  91. Letter by Chi and Marszalek Regarding Article, “Composite End Points in Clinical Research: A Time for Reappraisal”

    Article • Circulation, December 2017, Wolters Kluwer Health

    Gerald Chi

  92. Symptomatic Event Reduction with Extended-Duration Betrixaban in Acute Medically Ill Hospitalized Patients

    Article • American Heart Journal, December 2017, Elsevier

    Gerald Chi

  93. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial

    Article • Thrombosis and Haemostasis, December 2017, Schattauer GmbH

    Gerald Chi

  94. Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, December 2017, Elsevier

    Gerald Chi

  95. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy

    Article • Journal of Thrombosis and Thrombolysis, September 2017, Springer Science + Business Media

    Gerald Chi

  96. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis

    Article • Journal of Thrombosis and Haemostasis, September 2017, Wiley

    Gerald Chi

  97. P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  98. P4316N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  99. P5600History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  100. P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  101. P6112Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  102. P5599Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  103. P1551D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely Ill medical patients: insights from the APEX trial

    Article • European Heart Journal, August 2017, Oxford University Press (OUP)

    Gerald Chi

  104. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials

    Article • American Heart Journal, July 2017, Elsevier

    Dr Gerald Chi, Gerald Chi

  105. Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

    Article • Journal of the American Heart Association, July 2017, Wolters Kluwer Health

    Gerald Chi, Professor Yousef Khader

  106. The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Gerald Chi

  107. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

    Article • TH Open, June 2017, Thieme Publishing Group

    Gerald Chi

  108. Commentary: Extended-Duration betrixaban reduces the risk of stroke versus standard-Dose enoxaparin among hospitalized medically Ill patients

    Article • Journal of Neurology and Neuromedicine, May 2017, Sciaccess Publishers LLC

    Gerald Chi

  109. Erratum

    Article • Expert Review of Cardiovascular Therapy, April 2017, Taylor & Francis

    Gerald Chi

  110. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors

    Article • Expert Review of Cardiovascular Therapy, March 2017, Taylor & Francis

    Dr Gerald Chi, Gerald Chi

  111. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2016, New England Journal of Medicine (NEJM/MMS)

    Gerald Chi

  112. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

    Article • Circulation, December 2016, Wolters Kluwer Health

    Gerald Chi

  113. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyClinical Perspective

    Article • Circulation, November 2016, Wolters Kluwer Health

    Dr Gerald Chi, Gerald Chi

  114. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill PatientsClinical Perspective

    Article • Circulation, November 2016, Wolters Kluwer Health

    Dr Gerald Chi, Gerald Chi, Professor Yousef Khader

  115. Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)

    Article • The American Journal of Cardiology, September 2016, Elsevier

    Dr Gerald Chi, Gerald Chi

  116. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2016, New England Journal of Medicine (NEJM/MMS)

    Gerald Chi, Professor Yousef Khader

  117. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis

    Article • Circulation Cardiovascular Interventions, May 2016, Wolters Kluwer Health

    Dr Gerald Chi, Gerald Chi

  118. THE ASSOCIATION BETWEEN LEFT VENTRICULAR MASS AND MEASURES OF INFARCT SIZE IN ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE EMBRACE STEMI CLINICAL TRIAL

    Article • Journal of the American College of Cardiology, April 2016, Elsevier

    Dr Gerald Chi, Gerald Chi

  119. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention

    Article • European Heart Journal, November 2015, European Society of Cardiology

    Gerald Chi

  120. d-Dimer elevation and adverse outcomes

    Article • Journal of Thrombosis and Thrombolysis, July 2014, Springer Science + Business Media

    Dr Robert John Mentz, Dr Gerald Chi, Gerald Chi

  121. Scleroderma and failed response to alefacept

    Article • Rheumatology, June 2005, Oxford University Press (OUP)

    Gerald Chi